The presence of rheumatological conditions is not a risk factor of long-term post-COVID symptoms after SARS-CoV-2 infection: a multicenter study

Fernández‐de‐las‐Peñas, César; Martín-Guerrero, José D.; Navarro‐Pardo, Esperanza; Fuensalida‐Novo, Stella; Palacios‐Ceña, María; Velasco-Arribas, María; Pellicer-Valero, Óscar J.

doi:10.1007/s10067-021-05935-w

Cited by 8 publications

(16 citation statements)

References 11 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 They found no association of RMD with long-term post-COVID-19 symptoms, but they may have been underpowered to detect a statistical association (OR 1.46, 95% CI 0.89 to 2.40, p=0.15) and RMD may have included non-systemic conditions. 23 Overall, our results also suggest that many people with SARDs who develop COVID-19 may have symptom duration similar to the general population. However, there were a minority of people with SARDs who experienced lengthy symptom duration.…”

Section: Discussionmentioning

confidence: 95%

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

et al. 2022

View full text Add to dashboard Cite

ObjectiveWe investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs).MethodsWe analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression.ResultsWe identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81).ConclusionMost people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.

show abstract

Section: Discussionmentioning

confidence: 95%

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

et al. 2022

View full text Add to dashboard Cite

show abstract

“…All participants were assessed a mean of 8.4 months (SD, 1.5) after hospital discharge. The features of the total sample are shown in Table 1 [ 16 , 17 , 18 , 19 , 20 , 21 ].…”

Section: Resultsmentioning

confidence: 99%

“…Participants provided their informed consent before collecting any data. It should be noted that the participants from the LONG-COVID-EXP-CM study have been referred to in previous letters to the editor or publications [ 16 , 17 , 18 , 19 , 20 , 21 ] but current data presented here are completely new and not previously published.…”

Section: Methodsmentioning

confidence: 99%

Psychometric Properties of the Hospital Anxiety and Depression Scale (HADS) in Previously Hospitalized COVID-19 Patients

Fernández‐de‐las‐Peñas

Rodríguez‐Jiménez

Palacios‐Ceña

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is associated with psychological/emotional disturbances. This study aimed to assess internal consistency, reliability, and construct validity of the Hospital Anxiety and Depressive Scale (HADS), as a patient-reported outcome measure (PROM) for evaluating emotional consequences of SARS-CoV-2 in hospitalized COVID-19 survivors with long COVID. The LONG-COVID-EXP-CM is a multicenter cohort study including patients hospitalized by COVID-19 during the first wave of the pandemic in five hospitals in Madrid. A total of 1969 (age: 61 ± 16 years, 46.5% women) COVID-19 survivors experiencing post-COVID symptoms a mean of 8.4 ± 1.5 months after hospital discharge completed HADS. Internal consistency (Cronbach α), reliability (item-internal consistency, item-discriminant validity), construct validity (confirmatory factor analysis), and floor effect and ceiling effect were calculated. The mean time for fulfilling HADS was 65 ± 12 s. A ceiling effect ranging from 1.99% to 13.74% and a floor effect ranging from 43.05% to 77.77% was observed. Based on the item-scale correlation coefficients, the Cronbach’s alpha values reflecting the internal consistency reliability were 0.890 for the anxiety scale (HADS-A) and 0.856 for the depressive scale (HADS-D) The correlation coefficient between HADS-A and HADS-D scores was excellent (r: 0.878). The confirmatory factor analysis revealed that five out of the seven fitness indexes were excellent: CFI = 0.969, NNFI = 0.963; TLI = 0.963; AGFI = 0.951; GFI = 0.972), supporting good construct validity. In conclusion, this study indicates that both anxiety and depressive symptoms scales of HADS had overall good psychometric properties to be used for assessing psychological and emotional stress in COVID-19 survivors with long COVID.

show abstract

“…The Spanish post-hospitalization study found a similar distribution of persistent COVID-19 symptoms in SARDs and non-SARDs patients [30] , but the latter group was also seen in rheumatology clinic and may not reflect the general population. Another post-hospitalization study found no association of SARDs with post-acute COVID-19 symptoms, but only identified 31 patients with SARDs so may have been underpowered [33] . Finally, a study performed in New York City found that a similar proportion of SARDs and non-SARDs had “long-hauler” status, but all were seen in rheumatology clinic [32] .…”

Section: Discussionmentioning

confidence: 99%

DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study

Iorio

Cook

Vanni

et al. 2022

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

The presence of rheumatological conditions is not a risk factor of long-term post-COVID symptoms after SARS-CoV-2 infection: a multicenter study

Cited by 8 publications

References 11 publications

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Psychometric Properties of the Hospital Anxiety and Depression Scale (HADS) in Previously Hospitalized COVID-19 Patients

DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study

Contact Info

Product

Resources

About